Read the Neurology journal article: Urinary p75ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS Please refer to the following press releases for more information: University of Miami Miller School of Medicine Press Release Flinders University Press Release ALZ Forum Article ALS Association Press Release NIH News Release
Please refer to links below for further detail: University of Miami Miller School of Medicine Press Release http://www.alsa.org/news/media/press-releases/trial-of-arimoclomol-120916.html http://orphazyme.com/index.php/news/news-releases/73-phase-ii-arimoclomol-als-sod1
Dr. Benatar is hosting a webinar in partnership with ALSA to discuss The CReATe Consortium research program. Patients, families, and friends are all invited to join!
MIAMI, FL –The National Center for Advancing Translational Sciences and the National Institute of Neurological Disorders and Stroke have granted a $6.24 million cooperative agreement award to Dr. Michael Benatar for the establishment of a Rare Diseases Clinical Research Consortium. The consortium, to be called CReATe (Clinical Research in ALS and related disorders for Therapeutic […]
MIAMI, FL – 305 Films and the ALS Recovery Fund have teamed up to produce the short film “Who is Lou Gehrig?” taking audiences into the mind of Jeff Fogel; an active Miami native who was diagnosed with ALS three years ago. The movie follows Fogel’s life with ALS but takes a unique approach by […]
MIAMI, FL – The Principal Investigator at the University of Miami announced that enrollment has closed for the FDA-sponsored phase II/III randomized, double-blind, placebo-controlled trial of the experimental drug Arimoclomol, in SOD1+ familial ALS. This administrative decision to close enrollment at the end of the phase II component was made in consultation with the trial’s […]
The Miller School’s Michael Benatar, M.D., Ph.D., associate professor of neurology, was part of an international team of researchers that discovered two new genetic causes of a multi-system degenerative disorder that typically affects the brain, muscle and bone, and of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. Published March 3 in the journal Nature, […]
The ALS Recovery Fund, a steadfast ally in the fight against ALS, has pledged another $1 million to the Department of Neurology at the University of Miami for its continued ALS research and patient support. The gift will expand upon the Miller School’s existing programs and provide additional resources, including researchers and a dedicated health […]
This week, Neurology, the official journal of the American Academy of Neurology (AAN) features an interview with Dr. Benatar about the Pre-fALS study. To listen to the podcast, please click on the link below and scroll down (if necessary) to the October 16, 2012 podcast entitled “Pre-Symptomatic Studies in ALS: Rationale, Challenges and Approach”. Neurology […]
The ALS Recovery Fund has been a major supporter of ALS research and patient care at the University of Miami. The annual run/walk will be held on Saturday, May 12th at 7:30 am at the Dinner Key Auditorium on South Bayshore Drive. Click the ALS Recovery Fund logo to learn more.
For a long time scientists have known that, on chromosome 9, there is a gene of great importance to both ALS and frontotemporal dementia (FTD). This gene has however remained elusive…until now: Thanks to the participation of fALS patients and their families in our research studies, we have been able to contribute to the efforts […]
fALS Connect is an online registry for people with familial ALS as well as their family members. fALS Connect aims to connect fALS families with scientists who are engaged in fALS research. Both affected individuals as well as unaffected family members are encouraged to sign up. Click the fALS Connect logo to learn more.
Dr. Benatar and colleagues at NIH (Dr. Traynor), Italy (Dr. Chio) and St. Jude’s hospital (Dr. Taylor) recently identified mutations in the VCP (valosin-containing protein) gene as a cause of familial ALS. The ALS Association has since awarded Dr. Benatar and Dr. Taylor a grant to further study the relationship between VCP and ALS. Read […]
Dr. Benatar and Dr. Fernando Vieira recently co-hosted an ALS-TDI webinar in which they discuss what is known about the genetics of ALS, how this information is being used in the lab to identify biological pathways and potential therapeutics, as well as an overview of current clinical research activities and opportunities for patients and families […]
Dr. Benatar recently attended Net Change Week, an annual event hosted by the Social Innovation Generation (SiG) at the MaRS Discovery District in Toronto, where he led one of the Future Lab teams. Net Change Week is dedicated to exploring the intersection between social technology and social change. The Future Labs bring people with expertise […]
The Pre-fALS study is growing, so we are expanding our research team! Mike is a recent graduate of Emory University, where he majored in Neuroscience and Behavioral Biology. He will be assisting Sue with the Pre-fALS study. In addition to study logistics, Mike will play an active role in subject enrollment and data collection. Mike […]
Thanks to everyone who traveled to Washington, DC for ALS Advocacy Day. Our familial ALS session was a great success. Dr. Benatar spoke for about 45 minutes, followed by a lively Q&A session. After the talk, we all enjoyed pizza and soda while discussing the special needs of fALS patients and their family members who […]